Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Fuji
Boehringer Ingelheim
Chubb
Julphar
Daiichi Sankyo

Generated: August 18, 2019

DrugPatentWatch Database Preview

Litigation Details for GILEAD SCIENCES, INC. v. Mylan Inc. (N.D.W. Va. 2014)

  Try a free trial


See Plans and Pricing

« Back to Dashboard

GILEAD SCIENCES, INC. v. Mylan Inc. (N.D.W. Va. 2014)

Docket ➤ Sign Up Date Filed 2014-06-09
Court District Court, N.D. West Virginia Date Terminated 2015-11-02
Cause 28:1338 Patent Infringement Assigned To Irene Patricia Murphy Keeley
Jury Demand None Referred To Magistrate Judge Michael John
Parties EMORY UNIVERSITY; GILEAD SCIENCES, INC.; MYLAN INC.; MYLAN PHARMACEUTICALS INC.
Patents 5,814,639; 6,642,245; 6,703,396; 8,592,397; 8,716,264
Attorneys Adam S Ennis; Brian H. Pandya; Cedric C.Y. Tan; Chad L Taylor; Christine E. Duh; Christopher Borello; Christopher C. Kennedy; Colleen Tracy James; David A. Manspeizer; David B. Bassett; E. Ryan Kennedy; Floyd B. Chapman; Frank E. Simmerman , Jr.; Frank Edward Simmerman , III; George J Barry , III; Gordon H. Copland; James H. Wallace , Jr.; Jared C. Bunker; Jay R. Deshmukh; Jessica M. Hauth; Jonathan E. Barbee; Karen Cassidy; Karin A. Hessler; Kate Saxton; Mark A. Pacella; Meghan M. Rachford; Richard W. Gallagher; Robert J. Scheffel; Ryann M. Muir; Scott A. McMurry; Thomas Krzeminski; Timothy H. Kratz; Vinita Ferrera; Wesley E. Weeks; William J O'Brien; William O. Adams; William Zimmerman
Link to Docket External link to docket
Small Molecule Drugs cited in GILEAD SCIENCES, INC. v. Mylan Inc.
The small molecule drugs covered by the patents cited in this case are ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , and ➤ Sign Up .

Details for GILEAD SCIENCES, INC. v. Mylan Inc. (N.D.W. Va. 2014)

Date Filed Document No. Description Snippet Link To Document
2014-06-09 1 30. United States Patent No. 6,642,245 (“the ’245 Patent,” copy attached as Exhibit A),… Infringement of U.S. Patent No. 6,642,245 40. Plaintiffs repeat…Exhibit A - Patent Information, # 2 Exhibit A/Pt. 2 - Patent Information, # 3 Exhibit B - Patent Information…Information, # 4 Exhibit C - Patent Information, # 5 Exhibit C/Pt. 2 - Patent Information, # 6 Civil Cover Sheet… 1. This is an action for patent infringement under the patent laws of the United States, Title External link to document
2015-03-02 105 infringement of U.S. Patent Nos. 6,642,245 (the “’245 patent”), 6,703,396 (the “’396 patent”), and 8,592,397…infringement of a fourth patent, U.S. Patent No. 8,716,264 (the “’264 patent”). (D.I. 94.) (The ‘245… ‘396 patents are referred to herein as the “FTC Patents,” and the ‘397 and ‘264 patents are referred…before the United States Patent and Trademark Office of the patent applications leading to…before the United States Patent and Trademark Office of the patent applications leading to External link to document
2015-03-02 106 United States Patent and Trademark Office (“USPTO”) issued United States Patent No. 6,642,245 (the “’245… ’245 patent, including but not limited to the right to sue for infringement of the ’245 patent. …the USPTO issued United States Patent No. 6,703,396 (the “’396 patent”), entitled “Method of Resolution… ’396 patent, including but not limited to the right to sue for infringement of the ’396 patent. …the USPTO issued United States Patent No. 8,592,397 (the “’397 patent”), entitled “Compositions and Methods External link to document
2015-03-26 125 Exhibit Decl of Wm Adams and Exh. 1-3 terms of U.S. Patent Nos. 6,642,245 (“the ’245 Patent”), 6,703,396 (“the ’396 Patent”), 8,592,397 (… (“the ’397 Patent”), and 8,716,264 (“the ’264 Patent”) that are in dispute and proposed constructions…asserting Claim 6 of the ‘245 Patent; Claims 1, 3-5, 13, 15, and 16 of the ‘396 Patent; Claims 1-6, 14-16, 19…24-26 of the ‘397 Patent; and Claims 1-3, 9-17, 25, 33, and 34 of the ‘264 Patent (collectively, “the…the currently Asserted Claims. I. ‘245 Patent External link to document
2015-03-30 127 Its Proposed Claim Constructions for U.S. Patent Nos. 8,592,397 and 8,716,264, that this term is a limitation…;s performance of its duty as the construer of patent claims.” Indeed, the Federal Circuit has never …claim language when it decided to challenge the patents-in-suit— it alleged neither indefiniteness nor… 2 November 2015 1:14-cv-00099-IMK-MJA Patent None District Court, N.D. West External link to document
2015-03-31 128 the owner ofthe U.S. Patent Nos. 8,592,397 and 8,716,264 (“the ‘397 and ‘264 patents”). Co-plaintiffEmory…the following claim constructions I. U.S. Patent No. 8,592,397 TERM/PHRASE STIPULATED CONSTRUCTION …own, and has no interest in, the ‘397 and ‘264 patents. ActiVeUS 142 l 543 54V.l Case 1:14-cv-00099-…CONSTRUCTION emtricitabine” II. U.S. Patent No. 8,716,264 TERl\/l/PHRASE STIPULATED CONSTRUCTION… 2 November 2015 1:14-cv-00099-IMK-MJA Patent None District Court, N.D. West External link to document
2015-04-06 129 contained in U.S. Patent Nos. 8,592,397 (“the ‘397 Patent”) and 8,716,264 (“the ‘264 Patent”) (Dkt. No. 100… answering brief, arguing that one of Gilead’s patent claims is indefinite, regardless of how the Court…Emory does not own or hold an interest in either patent (Dkt. No. 100 at 6, fn. 6). Case 1:14-cv-00099-…is fatally indefinite, because “nothing in the patents or the prosecution histories discloses the conditions…amount of discovery will change the fact that the patent and its prosecution history” are silent as to External link to document
Date Filed Document No. Description Snippet Link To Document

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Boehringer Ingelheim
McKinsey
Julphar
Argus Health
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.